CVI Holdings’s Marker Therapeutics MRKR Stock Holding History

CVI Holdings’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,000	Closed	-$2.26M	–	47
2018 Q3	$2.26M	Hold	25,000	–	–	3.74%	10
2018 Q2	$2.36M	Buy	+25,000	New	+$1.27M	2.94%	10

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CVI Holdings's MRKR Position: Q4 2018 in Review

CVI Holdings sold out of Marker Therapeutics (MRKR) in Q4 2018, closing a stake of 25,000 shares — an estimated $2.26M sold.

CVI Holdings first reported a position in MRKR in Q2 2018 and held it in 2 quarters. The position peaked at $2.36M in Q2 2018. 43 funds tracked by Wall St. Rank hold MRKR as of Q4 2018.

CVI Holdings reported no remaining Marker Therapeutics position as of Q4 2018 after selling out during the quarter.
CVI Holdings sold 25,000 Marker Therapeutics shares in Q4 2018, an estimated $2.26M.
CVI Holdings first reported a position in Marker Therapeutics in Q2 2018 and held it in 2 quarters.
CVI Holdings's Marker Therapeutics position peaked at $2.36M in Q2 2018.
43 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2018.

Based on CVI Holdings's 13F filing for Q4 2018, filed 14 Feb 2019.